Clinical Trial: A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)

U.S., Dec. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07256301) titled 'A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)' on Nov. 20.

Brief Summary: This is a multicenter, open-label, Phase Ib clinical trial designed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of the humanized monoclonal antibody EA5 in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).

Study Start Date: Jan. 03, 2024

Study Type: INTERVENTIONAL

Condition: PNH - Paroxysmal Nocturnal Hemoglobinuria

Intervention: BIOLOGICAL: EA5

All treatments were given as IV infusions.

Recruitment Status: RECRUITING

Sp...